Citadel Advisors’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-21,603
| Closed | -$64K | – | 8328 |
|
|
2016
Q3 | $64K | Sell |
21,603
-451
| -2% | -$782 | ﹤0.01% | 6798 |
|
|
2016
Q2 | $33K | Sell |
22,054
-19,047
| -46% | -$43.6K | ﹤0.01% | 6507 |
|
|
2016
Q1 | $152K | Buy |
41,101
+24,674
| +150% | +$153K | ﹤0.01% | 5827 |
|
|
2015
Q4 | $166K | Sell |
16,427
-14,168
| -46% | -$171K | ﹤0.01% | 6059 |
|
|
2015
Q3 | $416K | Sell |
30,595
-97,289
| -76% | -$1.73M | ﹤0.01% | 5057 |
|
|
2015
Q2 | $2.43M | Buy |
127,884
+23,109
| +22% | +$500K | ﹤0.01% | 2835 |
|
|
2015
Q1 | $2.74M | Buy |
104,775
+91,898
| +714% | +$2.34M | ﹤0.01% | 2686 |
|
|
2014
Q4 | $270K | Buy |
12,877
+9,426
| +273% | +$238K | ﹤0.01% | 5594 |
|
|
2014
Q3 | $115K | Sell |
3,451
-98,496
| -97% | -$3.06M | ﹤0.01% | 6286 |
|
|
2014
Q2 | $3.27M | Buy |
101,947
+37,628
| +59% | +$1.4M | ﹤0.01% | 2239 |
|
|
2014
Q1 | $2.97M | Buy |
64,319
+36,786
| +134% | +$2.16M | ﹤0.01% | 2235 |
|
|
2013
Q4 | $1.95M | Buy |
27,533
+24,944
| +963% | +$1.91M | ﹤0.01% | 2576 |
|
|
2013
Q3 | $222K | Sell |
2,589
-11,862
| -82% | -$1.01M | ﹤0.01% | 4666 |
|
|
2013
Q2 | $915K | Buy |
+14,451
| New | +$767K | ﹤0.01% | 3267 |
|
Citadel Advisors's AEGR Position: Q4 2016 in Review
Citadel Advisors sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 21,603 shares — an estimated $64K sold.
Citadel Advisors first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $3.27M in Q2 2014. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- Citadel Advisors reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- Citadel Advisors sold 21,603 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $64K.
- Citadel Advisors first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- Citadel Advisors's Aegerion Pharmaceuticals position peaked at $3.27M in Q2 2014.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on Citadel Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.